SBH Sciences offers preclinical oncology drug development and validation services using miniaturized in vitro organoid systems. These models provide a more accurate, ethical, and personalized alternative to traditional animal testing and 2D cell cultures, making organoids a useful tool for research and drug development. We are developing next-generation 3D organoid models to help position you as an industry leader in biotech, offering ethical, animal-free solutions that advance the future of medicine.
In terms of drug development, organoids are useful for drug screening, testing, and mechanistic studies. Organoids provide a more accurate model for testing drug efficacy and toxicity, as compared to more traditional 2D cell cultures. They help in understanding how drugs interact with organ specific cells, which can lead to the development of more effective drugs. Not only do organoids allow for a more in vivo relevant model, but they also can reduce the need for animal testing in the early stages of drug development, which is both ethical and cost effective.
Specifically, organoids are proving to be a viable tool in cancer research, particularly in the development and testing of treatments. Organoids provide the ability to model cancer more accurately than traditional 2D methods. Organoids can be grown from cancer cells taken directly from a patient’s tumor, allowing researchers to mimic the 3D structure and cellular diversity of actual tumors more closely than 2D cell cultures. Tumors are often composed of a diverse array of cell types.
Organoids can maintain this heterogeneity, which is crucial for understanding how different cancer cells within a given tumor may respond to treatments. This also allows for patient specific drug responses in personalized medicine, by creating organoids from patient tumor cells, testing how that individual’s cancer responds to various treatments. This approach can help identify the most effective and least toxic treatment for each patient.
Organoids provide a more accurate model than animal testing or 2D cell cultures to assess the efficacy and safety of cancer treatments, due to their complexity and relevance to human biology.
Organoids are used to model diseases, allowing researchers to study the pathology and progression of diseases such as:
SBH Sciences works in partnership with Bonds Biosystems, a company working on the development of human physiologically relevant organoids to provide in vitro 3D solutions to aid in disease understanding and treatment development. Specifically, Bonds Biosystems grows human mini organs: fat organoids and heart organoids relevant to obesity and cardiometabolic diseases, respectively. Their work focuses on helping to bring solutions to the growing obesity epidemic. More than 40% of the United States population is obese, with more than 70% considered overweight. They are working to aid the development of drugs via their 3D BioSol™ platform of mini organs, engineering and manufacturing scaffold free adipose tissue and heart models, with vascular organoids in the works.
At SBH Sciences we assist in providing meaningful readouts via our vast list of cell-based assay services. Please contact us to see how we can help accelerate your drug discovery and development.
Zhao, Z., Chen, X., Dowbaj, A. M., Sljukic, A., Bratlie, K., Lin, L., Fong, E. L., Balachander, G.M., Chen, Z., Soragni, A., Huch, M., Zeng, Y. A., Wang, Q., & Yu, H. (2022). Organoids. Nature Reviews Methods Primers, 2(1). https://doi.org/10.1038/s43586-022-00174-y
Jiang, X., Oyang, L., Peng, Q., Liu, Q., Xu, X., Wu, N., Tan, S., Yang, W., Han, Y., Lin, J., Xia, L., Peng, M., Tang, Y., Luo, X., Su, M., Shi, Y., Zhou, Y., & Liao, Q. (2023). Organoids: opportunities and challenges of cancer therapy. Frontiers in cell and developmental biology, 11, 1232528. https://doi.org/10.3389/fcell.2023.1232528